Development of Liver Damage Treatment Technology Using Nanoparticle-Loaded Mesodermal Stem Cells

GIST Professor Taegiyoung and Joint Research Team Enhance Therapeutic Effect Using Prussian Blue Nanoparticles

[Asia Economy Reporter Kim Bong-su] The research team led by Professor Tae Ki-yong of the Department of New Materials Engineering at Gwangju Institute of Science and Technology (GIST), in collaboration with Professor Yang Hee-seok's team from the Department of Nano-Bio Medical Science at Dankook University, announced on the 20th that they have developed a technology to suppress ischemic liver damage using mesenchymal stem cells loaded with biocompatible nanoparticles.

The team succeeded in enhancing the survival rate and improving the release of therapeutic factors by loading Prussian Blue (PB) nanoparticles onto mesenchymal stem cells (MSCs), which have difficulty surviving in tissues damaged by reactive oxygen species. Prussian Blue (PB) is a biocompatible nanoparticle approved by the U.S. Food and Drug Administration (FDA) as a drug and is also used as a contrast agent for magnetic resonance imaging (MRI) and as a photothermal therapy agent.

When applied to rats with liver ischemia-reperfusion symptoms, MSCs loaded with nanozyme (PB-MSC) not only reduced necrosis in liver tissue compared to regular MSCs but also accelerated functional recovery.

Professor Tae Ki-yong stated, “This research outcome can be applied to enhance the survival and therapeutic performance of various cells beyond mesenchymal stem cells, and it can be used for regeneration of various organs and tissues beyond ischemia-reperfusion. It presents an important potential to comprehensively improve the efficacy of cell therapies for tissue regeneration.”

The research results were published online on the 11th in the prestigious journal of the American Chemical Society, ‘ACS Applied Materials & Interfaces.’

This content was produced with the assistance of AI translation services.